Financial Performance - For the year ended December 31, 2023, the company's revenue was approximately RMB 618.1 million, an increase of about RMB 102.1 million or 19.8% compared to RMB 516.0 million for the year ended December 31, 2022, primarily driven by sales growth of BA1101 and BA6101 in China [6]. - The gross profit for the year ended December 31, 2023, was approximately RMB 408.9 million, an increase of about RMB 54.7 million or 15.4% compared to the previous year [8]. - The net loss for the year was RMB 119.4 million, a significant reduction of 64.0% compared to the previous year [12]. - Revenue increased by 19.8% to RMB 618.1 million compared to 2022, demonstrating the ability to maintain market share in the biopharmaceutical sector [16]. - The company reported a total comprehensive loss of RMB 119,149,000 for the year, compared to RMB 330,046,000 in 2022, indicating improved overall performance [187]. Cost and Expenses - The cost of sales increased from RMB 161.7 million for the year ended December 31, 2022, to approximately RMB 209.2 million for the year ended December 31, 2023, representing about 33.9% of total revenue in the same year (2022: 31.3%) [7]. - Sales and distribution expenses for the year ended December 31, 2023, were RMB 256.5 million, an increase of RMB 42.4 million or 19.8% compared to RMB 214.1 million for the year ended December 31, 2022, consistent with revenue growth [9]. - Research and development expenses for the year ended December 31, 2023, were approximately RMB 230.7 million, a decrease of about RMB 169.6 million compared to RMB 400.3 million for the year ended December 31, 2022, mainly due to four R&D projects progressing to Phase III clinical trials [10]. - Administrative expenses decreased significantly from RMB 82.3 million for the year ended December 31, 2022, to RMB 51.7 million for the year ended December 31, 2023, due to reduced costs associated with the global offering [49]. Research and Development - The company has six projects in the pipeline, with BA1102 currently under BLA review in China and BA5101 and BA9101 having completed Phase III clinical trials [12]. - The company is actively expanding its product pipeline with multiple candidates in various stages of clinical development [22]. - The company has 29 innovative antibody and antibody-drug conjugate candidates, with 17 patents successfully granted and others pending [67]. - The company is committed to innovation, as evidenced by its ongoing patent applications for new therapeutic candidates [67]. Production and Capacity - The company is expanding its production capacity with multiple pilot and commercial production lines, enhancing scale efficiency [14]. - As of the report date, the company has a commercial production capacity of 9,000L and pilot production capacity of 700L, with multiple production lines under construction [18]. - The manufacturing base in Yantai covers approximately 84,474 square meters, with a total production capacity of 700L for pilot production and 9,000L for commercial production [33]. Market and Commercialization - The company has two commercialized products, with a strong focus on innovative antibody development across multiple therapeutic areas [15]. - Boyuno® has been included in the latest National Medical Insurance Drug List in China for all five indications as of December 2023 [16]. - The company has granted exclusive rights to Chengda Pharmaceutical (Qingdao) Co., Ltd. for the commercialization of Boyuno® in mainland China [16]. - The company aims to achieve profitability in the near term while focusing on becoming a leading global biopharmaceutical company in the long term [14]. Governance and Management - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including over 35 years in accounting and auditing [70]. - The board consists of seven members, including two executive directors, two non-executive directors, and three independent non-executive directors as of December 31, 2023 [135]. - The company emphasizes the importance of independent oversight from its supervisors, with members having significant experience in finance and management [79]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value [133]. Financial Position - As of December 31, 2023, the company's cash and cash equivalents were RMB 201.9 million, a decrease of 13.5% from RMB 233.5 million as of December 31, 2022 [54]. - The company's total equity decreased to RMB 1,319,868,000 from RMB 1,418,377,000, reflecting a decline of 6.9% [190]. - The company’s total assets minus current liabilities stood at RMB 1,670,037,000, down from RMB 1,730,888,000 in 2022 [189]. - The company’s financial statements must be prepared in accordance with International Financial Reporting Standards and the Hong Kong Companies Ordinance [183]. Environmental and Social Responsibility - The company is committed to environmental sustainability and adheres to relevant environmental laws and regulations in China [93]. - The company promotes green measures and awareness in daily operations to fulfill its environmental protection commitments [93]. - The company encourages employee awareness of environmental protection and implements various green office measures [93]. Risks and Challenges - The company faces various risks that may impact its financial condition and operational performance, including market, operational, investment, and financial risks [87][88][90][92]. - The company has established risk management procedures to minimize significant risks that may affect its business objectives [92].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 截 至2023年12月31日止年度的 年度業績公告 | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

智通财经APP讯，博安生物(06955)公布，于2023年12月19日，该公司与兴业金租订立融资租赁协议，据 此，兴业金租将自该公司购买租赁资产并将于租赁期内向公司出租该租赁资产，惟可根据融资租赁协议 的条款及条件提早终止。 ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------|-------------------------------------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | 股份代號 : 6955 | 山東博安生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） | | | | | | | | 目錄 | --- | --- | --- | --- | |-------|-------|-------|----------------------------------| | | | | | | | | 2 | 公司概覽 | | | | 4 | 公司資料 | | | | 6 | 財務摘要 | | | | 7 | 管理層討論及分析 | | | | 24 | 其他資料 | | | | 29 | 獨立審閱報告 | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 截 至2023年6月30日止六個月的中期業績公告 | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Product Development and Commercialization - Shandong Boan Biotechnology has successfully commercialized two products: BA1101, a biosimilar to Bevacizumab, and BA6101, the world's first biosimilar to Denosumab[4]. - The company has 11 candidate drugs nearing commercialization, including BA1102 and BA9101, which are in the late stages of clinical trials[4]. - The company plans to submit multiple Biologics License Applications (BLA) for its candidate drugs in the next two years[4]. - BA1102 and BA6101 are also in preparation for clinical trials overseas, indicating the company's international expansion efforts[4]. - The company aims to accelerate the market entry of its drugs through a diversified commercialization strategy, including domestic and international markets[7]. - The company has formed strategic partnerships with companies like AstraZeneca and Zhengda Pharmaceutical to enhance product commercialization[7]. - The company has a robust product pipeline with two commercialized products, seven innovative antibodies, and four biosimilar candidates[21]. - BA1102, a biosimilar drug, has completed Phase III clinical trials and is currently under BLA submission in China[22]. - The company is actively pursuing business collaborations to expand its market presence and enhance its innovative product offerings[20]. - The company is focusing on expanding its market presence in Europe and the US for its biosimilar products, aiming for global sales[28]. Financial Performance - The company's revenue for the year ended December 31, 2022, reached approximately RMB 516.0 million, a significant increase of 225.1% compared to RMB 158.7 million for the year ended December 31, 2021[10]. - Gross profit for the same period was approximately RMB 354.2 million, representing a year-on-year increase of 232.6%[12]. - The company recorded a net loss of RMB 331.7 million for the year ended December 31, 2022, compared to a net loss of RMB 240.5 million in 2020[15]. - The company's total equity decreased to RMB 1,418,377,000 from RMB 1,551,687,000, reflecting a decline in shareholder value[179]. - The company reported a total revenue of RMB 515,960,000 for 2022, a significant increase of 225.5% compared to RMB 158,704,000 in 2021[177]. - The net loss attributable to the owners of the parent company was RMB 331,749,000, compared to a loss of RMB 225,417,000 in 2021, indicating a worsening financial performance[177]. Research and Development - Research and development expenses totaled approximately RMB 400.3 million, up by RMB 168.7 million from RMB 231.6 million in 2021, driven by increased investment in R&D projects[14]. - The company has expanded its R&D team to 285 members and secured 21 new patents globally as of December 31, 2022[23]. - The company’s ongoing research and development efforts are aimed at enhancing its product pipeline across various therapeutic areas, including oncology and autoimmune diseases[28]. - The company has established a comprehensive biopharmaceutical platform that integrates R&D, production, and commercialization, enhancing operational efficiency[6]. Market Strategy and Distribution - Shandong Boan Biotechnology's distribution network covers over 1,000 hospitals nationwide, demonstrating its strong commercialization capabilities[7]. - The company anticipates 2023 to be a year of significant revenue growth from commercialized products and accelerated innovation pipeline development[20]. - The company has made significant progress in obtaining medical insurance access for its products, which is expected to drive sustained sales growth[22]. - The company has established a customer complaint handling mechanism to enhance service quality[98]. Corporate Governance and Management - The company has a board composed of experienced members, including the CEO and R&D President, with over 24 years of experience in the pharmaceutical industry[68][69]. - The company has adopted a set of corporate governance standards that meet or exceed the standard code[5]. - The board consists of nine members, including two executive directors, three non-executive directors, and three independent non-executive directors[130]. - The company has established five board committees: Audit Committee, Remuneration Committee, Nomination Committee, Strategic Committee, and Environmental, Social and Governance Committee[129]. - The company emphasizes the importance of diverse experiences and skills among board members for effective governance[132]. Financial Management and Risk Assessment - The company has implemented risk management procedures to minimize financial risks, including interest rate, foreign exchange, credit, and liquidity risks[96]. - The company has established a framework for investment risk assessment to balance various investment risks and returns[94]. - The company has established clear responsibilities and powers within its organizational structure to ensure effective risk management and internal controls[154]. - The company has a policy for reviewing and monitoring compliance with legal and regulatory requirements[142]. Environmental and Social Responsibility - The company is committed to environmental sustainability and adheres to relevant environmental laws and regulations in China[97]. - The company encourages green practices and promotes environmental awareness among employees[97]. - The Environmental, Social, and Governance (ESG) Committee was established on March 27, 2023, to manage ESG-related risks and opportunities[152]. Employee and Shareholder Relations - The company employed a total of 745 employees as of December 31, 2022, up from 572 employees as of December 31, 2021, with employee costs amounting to RMB 121.4 million in 2022[65]. - The company has a commitment to independent oversight, as evidenced by the diverse backgrounds of its board members in various sectors[82]. - The company has established a shareholder communication policy to facilitate ongoing dialogue and information sharing with investors[159].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 截 至2022年12月31日止年度的 年度業績公告 | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...